GLP‑1s, Direct‑to‑Consumer Pricing, and the HRA Opportunity Most Employers Are Missing
Why the Compliance Answer You’re Getting May Not Be the Answer You Need
If your company offers health benefits, someone has probably asked about GLP‑1 coverage in the last six months. 
The drugs work, employees want access, and the sticker price through traditional pharmacy channels can run north of $1,000 per month per employee.
Direct‑to‑consumer platforms like TrumpRx.gov, Hims, Lilly Direct, and NovoCare now offer the same medications between $149 and $449 per month, cash pay. The obvious question: can we reimburse employees through an HRA for purchases made through these channels?
In most cases, yes. But the compliance advice most employers receive says otherwise, and the reason is worth understanding. The savings show up twice, once on the prescription and again at renewal, where pharmacy spend outside the plan does not feed the claims experience that drives next year’s pricing. The analysis is worth the effort.
What the Platform Terms Actually Say
Several direct‑to‑consumer platforms include terms that restrict reimbursement from “insurance.” TrumpRx.gov, for example, requires buyers to confirm they will not seek reimbursement from any “insurance plan” or count purchases toward a deductible.
Lilly Direct, the manufacturer channel for Zepbound, is more nuanced than many employers assume. Lilly Direct orders are fulfilled through Gifthealth, a cash‑pay pharmacy platform. The checkout prohibits reimbursement from insurance carriers, third‑party payers, and federal or state programs, but it does not name HSAs, FSAs, HRAs, or other account‑based arrangements among the restricted categories.
The same flow expressly invites account‑based reimbursement, with a receipt page stating: “If you plan on using a HSA/FSA to reimburse this expense, or would like a receipt of your payment, please enter your email address to receive a copy.” The platform restricts insurance reimbursement and accommodates account‑based reimbursement. That distinction matters and is exactly the distinction most standard compliance summaries flatten.
Hims expressly permits FSA and HSA payment. Ro operates through an insurance concierge model. The landscape is not uniform, and the analysis has to be platform‑specific.
Why Employers Keep Getting the Same Answer
Employers exploring direct‑to‑consumer GLP‑1 reimbursement tend to run into the same wall. The question goes to the usual advisors, and the answer that comes back is some version of “it’s too risky.” No detailed analysis, no parsing of the specific platform terms, no evaluation of how the employer’s HRA is actually structured. Just a conclusion. Most employers accept the conclusion and move on, assuming that if their benefits professionals said no, there must be a reason worth deferring to.
That answer is correct for the brokers and vendors the employer is asking. It does not answer the employer’s question. The employer’s question is whether the attestation language actually prohibits what the employer is trying to do, which depends on the structure of the HRA, the specific platform terms, and the legal distinction between employer‑funded reimbursement and “commercial insurance.” That analysis has to come from someone on the employer’s side of the table.
A second dynamic reinforces the first. The pharmacy benefit ecosystem is extraordinarily consolidated. The major carriers each own or are aligned with PBMs, group purchasing organizations, specialty pharmacies, and third‑party administrators. A prescription can start with the carrier’s plan, flow through its PBM, be filled at its specialty pharmacy, and generate rebate revenue that stays within the same corporate family. Direct‑to‑consumer channels bypass that stack entirely. The employer pays less, the employee pays less, and the traditional intermediaries lose the margin.
Many of the brokers and vendors advising employers operate as partners of, or depend on access to, those same integrated carriers. The natural caution of the broker‑vendor compliance response is reinforced by a commercial alignment most employers are not aware of. It is not a conspiracy. It is how the market is built.
What the Employer‑Side Analysis Looks Like
An HRA is almost certainly not “commercial insurance.” It is a self‑insured, employer‑funded reimbursement arrangement, not an insurance product, with no underwriter and no risk transfer. The term “commercial insurance” in platform attestations is rooted in the pharmaceutical rebate ecosystem and is aimed at preventing double‑dipping between manufacturer discounts and insurance carrier payments. A self‑insured employer reimbursement does not fit that frame.
Transaction structure matters. In a participant‑directed HRA, which is how most HRAs operate, the employee pays at the point of sale and submits for reimbursement afterward. The employee is a cash‑paying customer at the point of purchase. Reimbursement comes later, from a separate employer‑funded account. That is the same structure under which Hims and Lilly Direct/Gifthealth affirmatively permit HSA and FSA reimbursement.
Plan design matters too. An integrated HRA functions as an extension of the employer’s group medical coverage. An excepted benefit HRA is structurally independent from the major medical plan and carved out of the ACA commercial market reforms entirely. Both support participant‑directed reimbursement; the EBHRA’s structural independence provides additional separation from the “commercial insurance” framework that platform attestations target.
What Employers Should Do
Get independent counsel involved.
The compliance analysis coming from your broker and benefits vendor is calibrated to their risk, not yours. An independent benefits attorney can evaluate the specific platforms, the structure of your HRA, and the actual exposure. The analysis may well conclude the risk is manageable.
Focus on transaction structure and HRA design.
A participant‑directed, submit‑for‑reimbursement HRA makes the employee a cash‑paying customer. Whether an integrated HRA, an EBHRA, or another arrangement fits best depends on your plan design and goals. Counsel can help you choose.
Ask who benefits from the status quo.
When you get pushback on a direct‑to‑consumer strategy, it is fair to ask whether the broker, the vendor, their parent companies, or their preferred partners has a financial stake in prescriptions staying in the traditional channel. The question is due diligence.
Be cautious with rebate‑based alternatives.
If the pitch is a PBM rebate pass‑through, make sure you understand the math, the transparency you actually have, and whether the savings survive audit. Direct‑to‑consumer pricing with HRA reimbursement is often simpler and more predictable.